Table 2.
eCDSS and Outcomes: Intention-to-Treat Analyses at 12 months(N=524)
| Usual Care (N=188 patients, 27 PCPs) N (%) |
CDSS (N=165 patients, 25 PCPs) N (%) |
CDSS Plus (N=171 patients, 28 PCPs) N (%) |
Total (N=524 patients, 80 PCPs) N (%) |
p-value | |
|---|---|---|---|---|---|
| Clinical Primary and Secondary Outcomes | |||||
| Change in systolic BP (mmHg) **, mean ± SD | −2.1 ± 18.2 | −2.8 ± 20.9 | −1.1 ± 20.2 | −2.0 ± 19.7 | 0.7 |
| Change in diastolic BP (mmHg) **, mean ± SD | −0.2 ± 10.4 | 0.1 ± 12.0 | −0.4 ± 10.8 | −0.2 ± 11.0 | 0.9 |
| Controlled BP** (<140/90 mmHg) | 109 (65) | 114 (74) | 100 (63) | 323 (67) | 0.1 |
| CKD Awareness- Process Outcome | |||||
| PCP awareness of CKD diagnosis at study end (inclusion on problem list or visit diagnosis) | 88 (47) | 86(52) | 86(50.3) | 260 (50) | 0.7 |
| New PCP awareness – new diagnosis from study baseline | 14 (16) | 23 (26) | 32 (32) | 69 (25) | 0.09 |
| Secondary Clinical Process outcomes | |||||
| ACEi/ARB use *** | 95 (51) | 86 (52) | 75 (44) | 256 (49) | 0.3 |
| ACEi/ARB initiation (new use) | 5 (7) | 6 (9) | 3 (4) | 14 (7) | 0.5 |
| Statin therapy use*** | 112 (61) | 79 (49) | 94 (58) | 285 (56) | 0.03 |
| Statin therapy initiation (new use) *** | 3 (6) | 3 (5) | 4 (7) | 10 (6) | 0.9 |
| Diuretic use at end of study *** | 47 (25) | 35 (21) | 32 (19) | 114 (22) | 0.3 |
| Diuretic initiation (new use) | 5 (4) | 3 (3) | 1 (1) | 9 (3) | 0.4 |
*
p-values account for clustering of patients within physicians.
**
Only out of those 480 patients with valid BP measure during study period (number missing BP: 20 Usual Care, 11 CDSS, 13 CDSS PLUS)
***
ACEi/ARB, Statin therapy and Diuretic medication “use” includes only patients who are still on the medication at the end of the study period.